Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00272181 · ClinicalTrials.gov registry record · Phase 2
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase 2 study, sponsored by Sesen Bio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00272181: Clinical Trial Phase 2 study, sponsored by Sesen Bio.
NCT00272181 is a Phase 2 study that was terminated before completion, run by Sesen Bio. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00272181, a Phase 2 study, was terminated before completion, sponsored by Sesen Bio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, effectiveness, and recommended dose of Proxinium in North American patients with Squamous Cell Head and Neck Cancer
Interventions
- DRUG Proxinium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Why NCT00272181 stopped before completion
NCT00272181 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Proxinium is the first listed.
NCT00272181 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00272181 about?
NCT00272181 is a clinical study titled "Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer". The purpose of this study is to determine the safety, effectiveness, and recommended dose of Proxinium in North American patients with Squamous Cell Head and Neck Cancer
What is the current status of trial NCT00272181?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2006-01. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00272181?
The interventions under investigation include: Proxinium (DRUG).
Who is sponsoring clinical trial NCT00272181?
This trial is sponsored by Sesen Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00272181's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia